Terry N H, Meistrich M L, Roubein L D, Lynch P M, Dubrow R A, Rich T A
Department of Experimental Radiotherapy, University of Texas MD Anderson Cancer Center, Houston 77030, USA.
Br J Cancer. 1995 Aug;72(2):435-41. doi: 10.1038/bjc.1995.351.
Measurements of dynamic tumour cell kinetic parameters, particularly the potential doubling time (Tpot) may have potential as predictive assays for treatment outcome after radiotherapy. This paper details the distributions of Tpot and other kinetic and DNA content parameters measured in rectal cancers. Biopsies were taken from 119 patients approximately 6 h after infusion of 200 mg m-2 bromodeoxyuridine (BrdUrd). The samples were analysed by bivariate DNA/BrdUrd flow cytometry. The primary purpose of the study was to measure the kinetic parameters of labelling index (LI), duration of S-phase (TS) and Tpot. Secondarily, tumour DNA ploidy (DNA index) and S-phase fractions (SPFs) were also estimated from the univariate DNA histograms. The 101 evaluable patients were classified according to clinical stage as T2 (n = 12), T3 (n = 53), T4 (n = 28) or recurrent tumours (n = 8). Of the evaluable tumours, 73 were DNA aneuploid. The median LI, TS, and Tpot of the aneuploid tumours were 21%, 20 h and 3.3 days respectively. The calculated LI, TS, and Tpot of diploid tumours were subject to uncertainties because of the contribution of normal cells. The LI and SPF of all tumours were, however, significantly (P < 0.001) correlated, having a correlation coefficient of only 0.76. The wide distributions of values for LI (quartiles 13.5%, 26.9%) and Tpot (quartiles 2.4, 5.6 days) that were found are necessary baseline information if these parameters are to be useful in individual treatment selection or as predictors of treatment outcome.
动态肿瘤细胞动力学参数的测量，尤其是潜在倍增时间（Tpot），可能具有作为放射治疗后治疗结果预测性检测方法的潜力。本文详细介绍了在直肠癌中测量的Tpot以及其他动力学和DNA含量参数的分布情况。在输注200mg/m²溴脱氧尿苷（BrdUrd）约6小时后，从119例患者身上获取活检样本。通过双变量DNA/BrdUrd流式细胞术对样本进行分析。该研究的主要目的是测量标记指数（LI）、S期持续时间（TS）和Tpot的动力学参数。其次，还从单变量DNA直方图中估计肿瘤DNA倍体（DNA指数）和S期分数（SPF）。101例可评估患者根据临床分期分为T2（n = 12）、T3（n = 53）、T4（n = 28）或复发肿瘤（n = 8）。在可评估的肿瘤中，73例为DNA非整倍体。非整倍体肿瘤的LI、TS和Tpot中位数分别为21%、20小时和3.3天。由于正常细胞的贡献，二倍体肿瘤的计算LI、TS和Tpot存在不确定性。然而，所有肿瘤的LI和SPF显著相关（P < 0.001），相关系数仅为0.76。如果这些参数要用于个体治疗选择或作为治疗结果的预测指标，所发现的LI值（四分位数13.5%，26.9%）和Tpot值（四分位数2.4，5.6天）的广泛分布是必要的基线信息。
